Clinical Trial Update: Effect of Empagliflozin on NT-Pro Brain Natriuretic Peptide in Heart Failure Patients With Reduced Ejection Fraction [Phase 4]

View source ↗

Summary

Phase 4 trial update assessing the effect of empagliflozin on NT-proBNP in patients with heart failure with reduced ejection fraction.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: Alexandria University | Conditions: Heart Failure With Reduced Ejection Fraction | Phase 4 | Status: UNKNOWN